Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2017
At a glance
- Drugs ECCS 50 (Primary)
- Indications Raynaud's disease; Scleroderma; Systemic scleroderma
- Focus Registrational; Therapeutic Use
- Acronyms STAR
- Sponsors Cytori Therapeutics
- 07 Nov 2017 Data presented in a Cytori Therapeutics Media Release.
- 07 Nov 2017 According to a Cytori Therapeutics media release, full data analysis from this trial will be presented at 5th Systemic Sclerosis World Congress.
- 24 Jul 2017 Top-line 24- and 48-week results published in a Cytori Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History